title: Heart rate predicts outcomes in an implantable cardioverter-defibrillator population.
abstract: BACKGROUND
  Elevated heart rate (HR) is associated with adverse cardiovascular events and total mortality in the general population and in individuals with heart disease. Our hypothesis was that mean HR predicts total mortality and heart failure hospitalization in patients undergoing implantable cardioverter-defibrillator (ICD) implantation.
  
  
  RESULTS
  The Inhibition of Unnecessary RV Pacing With AV Search Hysteresis in ICDs (INTRINSIC RV) trial included 1530 patients undergoing ICD implantation. After implantation of a dual-chamber ICD, patients were followed for a mean of 10.4 months. The mean HR for 1436 patients over the follow-up period was determined from device histograms. Patients were grouped into strata by mean HR, and the relationship between the primary end point and mean HR was analyzed with Mantel-Haenszel ordinal chi(2) tests. Higher intrinsic (unpaced) HR was associated with greater risk of achieving the primary end point of death or heart failure hospitalization (P<0.001). Of patients with a mean HR <75 bpm, 5.8% died or were hospitalized for heart failure, whereas 20.9% with a mean HR >90 bpm achieved the same end point, a 3.6-fold difference (P<0.0001). In a multivariate model with the use of Cox regression, HR was a significant predictor with a hazard ratio of 1.34 (P=0.0001; 95% confidence interval, 1.19 to 1.50), as were age, New York Heart Association functional class, and percent right ventricular pacing, but it was independent of gender and beta-blocker dosing. When considered as continuous or discrete variables grouped by 5-bpm increments, HR remained a significant predictor.
  
  
  CONCLUSIONS
  In this ICD population, the mean intrinsic HR was strongly associated with outcomes.
  
  
  BACKGROUND
  http://www.clinicaltrials.gov. Identifier: NCT00148967.
authors.affiliation: Department of Medicine, University of Iowa Hospitals, 4426a JCP, 200 Hawkins Dr, Iowa City, IA 52242, USA.
authors.forename: Mastaneh
authors.initials: M
authors.lastname: Ahmadi-Kashani
authors.forename: David J
authors.initials: DJ
authors.lastname: Kessler
authors.forename: John
authors.initials: J
authors.lastname: Day
authors.forename: T Jared
authors.initials: TJ
authors.lastname: Bunch
authors.forename: Kira Q
authors.initials: KQ
authors.lastname: Stolen
authors.forename: Scott
authors.initials: S
authors.lastname: Brown
authors.forename: Salam
authors.initials: S
authors.lastname: Sbaity
authors.forename: Brian
authors.initials: B
authors.lastname: Olshansky
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017147:Defibrillators, Implantable; D005260:Female; D006333:Heart Failure / Q000401:mortality; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D012044:Regression Analysis; D012189:Retrospective Studies; D012727:Sex Characteristics; D016277:Ventricular Function, Left
chemical_list: D000319:Adrenergic beta-Antagonists